Bayer doubles sales forecast for Nexavar

German pharmaceutical firm, Bayer, has doubled the sales estimate for its experimental cancer drug Nexavar.

Speaking to analysts in London the company said that the drug is in the last stage of tests required to sell the drug for lung cancer, and it has also been lodged with regulators as a treatment for kidney cancer.

It is predicted that the drug, developed with Onyx Pharmaceuticals, will produce annual sales of more than 1 billion euros ($1.2 billion) at its peak.

Bayer also said blood-clotting agent Kogenate would raise higher than expected sales and upped its forecast to more than 1 billion euros. The drug is already Bayer’s biggest- selling health-care product.

Trasylol, used with Kogenate in open heart surgery, may bring in more than 500 million euros a year, the company said.

© Adfero Ltd